Axsome Therapeutics, Inc. (AXSM) News
Track canonical SquawkNews coverage tagged to AXSM, Axsome Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
AXSM Initiate with an Outperform, $310 PT @ BMO
AXSM Initiate with an Outperform, $310 PT @ BMO
EQUITY | Jul 21, 2026, 12:05 PM UTC
L
Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
() -- Axsome Therapeutics (AXSM) said Wednesday the US Food and Drug Administration accepted its new drug application for AXS-12 to treat cataplexy, or muscle weakness, in narcolepsy. A target review date of May 1, 2027,
REGULATION | Jul 15, 2026, 11:52 AM UTC
L
AXSM Axsome Therapeutics announces FDA Acceptance of new drug application for axs-12 for the treatment of cataplexy in narcolepsy Axsome The
AXSM Axsome Therapeutics announces FDA Acceptance of new drug application for axs-12 for the treatment of cataplexy in narcolepsy Axsome Therapeutics - FDA sets pdufa target action date of may 1, 2027 for axs-12 NDA - FD
REGULATION | Jul 15, 2026, 11:01 AM UTC
M
AXSM Initiates ADHD Trial
Axsome Therapeutics initiates FOCUS-3 Phase 3 trial of Solriamfetol in adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
EQUITY | Jun 26, 2026, 11:00 AM UTC